The management combines business and technical know-how and has more than 30 years of experience in the chemical modification of biologics.
Ralf Kraehmer, PhD, chemist
Chief scientific officer (CSO) and Business Development
Ralf Kraehmer PhD, co-founder of celares GmbH, studied chemistry in Leipzig, Germany. After a postdoctoral fellowship at the Natural Products and Glycotechnology Research Institute (Durham, NC, USA) he became senior scientist in the field of process chemistry, especially of contract GMP manufacturing of drug candidates for clinical testing at CarboGen (Switzerland). Subsequently he was head of synthetic chemistry at Medical Enzymes AG, where he was responsible for the development of polymer-based delivery systems for the modification of biotechnological drugs.
Frank Leenders, PhD, biotechnologist
Chief operating officer (COO)
Frank Leenders PhD, co-founder of celares GmbH, studied biotechnology in Berlin, Germany. As head of the manufacturing and development department of LIBB GmbH, he was responsible for in-vitro test systems for medical diagnostics. He then joined Medical Enzymes AG, where he was head of clinical development of modified protein drugs for anti-cancer and anti-HIV-therapy.
Guenther Paetz, economist
Chief financial officer (CFO)
Guenther Paetz, co-founder of celares GmbH, studied economics and business administration at the universities of Kiel, Germany and Zurich, Switzerland. After graduation and completion of a trainee program at Deutsche Kreditbank AG (Berlin, Germany) he worked as assistant to the management board, founded a subsidiary in the business field of real estate brokerage and was responsible for finance and sales controlling. He was head of financial and sales controlling at the internet service company Immobilienscout AG (Berlin, Germany) and gained valuable experience in managing biotechnology companies while working as commercial director at Medical Enzymes AG (Berlin, Germany).
Michael Sefkow, PhD, chemist
Business development manager (BD)
Michael Sefkow PhD, studied chemistry in Berlin, Germany. He received his PhD form the ETH Zürich. After a postdoctoral fellowship at Harvard University (Cambridge, MA, USA) Michael returned to Germany working on epothilones at the GBF (now HZI) in Braunschweig, Germany. He moved to the University of Potsdam for a habilitation and became Privatdozent at the faculty of science. Subsequently, Michael joint caprotec GmbH, a proteomics start-up in Berlin, Germany, as head of chemistry. He then joint Biosynth GmbH as business development and sales manager.